Bicycle Therapeutics PLC is a biopharmaceutical company at the forefront of developing a unique class of therapeutics known as bicyclic peptides. Founded in 2009 and headquartered in Cambridge, United Kingdom, the company has pioneered a novel approach that combines the advantages of small molecules and antibodies to create highly targeted and potent treatments for a range of diseases.
Bicyclic peptides, or "bicycles," are engineered molecules that incorporate two loops to form a stable and specific binding structure. This unique architecture allows bicycles to interact with disease-related targets with high affinity and selectivity, making them valuable tools for drug discovery and development.
The company's proprietary platform, known as the Bicycles® platform, enables the creation of bicycles that can be customized to target various disease-causing proteins and pathways. This platform holds the potential to address previously undruggable targets and provide innovative treatment options for a wide range of diseases, including cancer, cardiovascular disorders, and other therapeutic areas.
Bicycle Therapeutics' pipeline includes a diverse portfolio of investigational therapies that are being developed for various indications. These include both internal development programs and collaborations with pharmaceutical partners to leverage the potential of the Bicycles® platform across different therapeutic areas.
The company's innovative approach to drug discovery and development has attracted collaborations with leading pharmaceutical companies, enabling them to harness the power of bicyclic peptides to enhance their drug discovery efforts and target challenging diseases more effectively.